Related Experiment Video

Updated: Jul 6, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease

P Michael Ho1, David J Magid, Susan M Shetterly

  • 1Cardiology Section, Denver VA Medical Center, Denver, CO, USA. michael.ho@uchsc.edu

American Heart Journal
|March 29, 2008
PubMed

Insights

Medication nonadherence in coronary artery disease (CAD) patients significantly increases risks for mortality, hospitalizations, and revascularization. Improving adherence to beta-blockers, ACE inhibitors, and statins is crucial for better cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Limited understanding of medication nonadherence impact on coronary artery disease (CAD) patient outcomes.
  • Focus on cardiovascular mortality, hospitalizations, and revascularization procedures.

Purpose of the Study:

  • To investigate the association between nonadherence to key cardiovascular medications and adverse patient outcomes.
  • To quantify the risks associated with nonadherence to beta-blockers, ACE inhibitors, and statins in CAD patients.

Main Methods:

  • Retrospective cohort study of 15,767 CAD patients.
  • Medication adherence measured by proportion of days covered for beta-blockers, ACE inhibitors, and statins.
  • Multivariable Cox regression with time-varying covariate for nonadherence analysis over a median follow-up of 4.1 years.

Main Results:

  • Nonadherence rates: 28.8% for beta-blockers, 21.6% for ACE inhibitors, 26.0% for statins.
  • Nonadherence significantly associated with increased all-cause mortality (HRs 1.50-1.85) and cardiovascular mortality (HRs 1.53-1.66).
  • Consistent increased risks observed for cardiovascular hospitalizations and revascularization procedures.

Conclusions:

  • Nonadherence to cardioprotective medications is prevalent in CAD patients.
  • Nonadherence is linked to a wide array of adverse cardiovascular events.
  • Targeting medication nonadherence in quality improvement initiatives is recommended to enhance patient outcomes.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...